In humans, the hepatic expression of GlP-1R has also been questioned, even though earlier studies have reported its presence in human hepatocytes, and suggested that GLP1R decreased hepatic steatosis by modulating the insulin signaling pathway [16] or activating lipid oxidation [43]. This evidence concerns the gene INS and fatty liver disease.